Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDISARC: Durvalumab and Tremelimumab vs Doxorubicin in Soft Tissue Sarcoma
NCT03317457Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Dec 2017
- Primary completion
- Aug 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in soft tissue sarcoma (STS), sponsored by AIO-Studien. Started Dec 2017; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03317457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03317457.